Results 41 to 50 of about 29,065 (118)

Tirzepatide-induced ketoacidosis in non-diabetic patients

European Journal of Case Reports in Internal Medicine
Background: Tirzepatide is a novel glucagon-like peptide 1/glucose-dependent insulinotropic peptide (GLP-1/GIP) receptor agonist. It was recently approved for diabetes control and weight reduction in non-diabetic patients. Case description: We report the
Pathan Mohamad Rafe Iqbal, Ossama Sajeh Maadarani, Zouheir Ibrahim Bitar   +2 more
doaj   +1 more source

Should glucagon‐like peptide‐1 receptor agonist treatment be withheld in preoperative management?

Journal of Diabetes, 2023
Zachary Bloomgarden
doaj   +1 more source

Ectopic, hepatic GLP-1R agonism enhances the weight loss efficacy of GLP-1 analogues

Molecular Metabolism
Objectives: Unimolecular triagonists drive substantial weight loss in patients with obesity by engaging the glucagon-like peptide 1 receptor (GLP-1R) and glucose dependent insulinotropic polypeptide receptor (GIPR) to reduce food intake (FI) and the ...
Jonathan D. Douros, Megan Capozzi, Aaron Novikoff, Jacek Mokrosinski, Barent DuBois, Joseph Stock, Rebecca Rohlfs, Mikayla Anderson, Dominika J. Jedrzejcyk, Svend Poulsen, Erik Oude Blenke, Tomas Dago, Kasper Huus, Peder L. Nørby, Sune Kobberup, Marita Rivir, Joyce Sorrell, Stephanie A. Mowery, Daniel J. Drucker, David A. D'Alessio, Jonathan E. Campbell, Timo D. Müller, Diego Perez-Tilve, Brian Finan, Patrick J. Knerr   +24 more
doaj   +1 more source

Patient preferences for glucagon-like peptide-1 receptor–agonist treatment attributes

Patient Preference and Adherence, 2019
Vivian T Thieu,1 Susan Robinson,2 Tessa Kennedy-Martin,2 Kristina S Boye,1 Luis-Emilio Garcia-Perez1 1Global Patient Outcomes and Real-World Evidence, Eli Lilly and Company, Indianapolis, IN, USA; 2Kennedy-Martin Health Outcomes (KMHO), Brighton, UK ...
Thieu VT, Robinson S, Kennedy-Martin T, Boye KS, Garcia-Perez LE   +4 more
doaj  

Efficacy and tolerability of oral semaglutide in Japanese patients with type 2 diabetes mellitus: Analysis report from diabetes specialist clinics

Journal of Diabetes Investigation
Introduction Glucagon‐like peptide 1 receptor agonists (GLP1Ras) have emerged as pivotal agents in diabetes management and organ protection. However, their use is limited due to the necessity for injectable administration.
Tetsuaki Inokuchi, Yoshihide Fukumoto, Gendai Lee, Yoshifumi Yokomizo, Kokichi Tanaka, Michiko Chosa, Masaru Doi, Noboru Tamaki, Seiichi Goto, Kojiro Ichikawa, Kazuo Kobayashi   +10 more
doaj   +1 more source

Knowledge, Attitude and Practice about Glucagon-like Peptide-1 Receptor Agonist Among the Physicians of Prince Mohammed bin Abdulaziz Hospital & Primary Health Care, National Guard, Saudi Arabia

Journal of Pharmaceutical Research
Glucagon-like peptide-1 receptor agonist (GLP-1RA) is a newly approved medication in the management of Diabetes Mellitus. GLP-1RA has potential adverse effects and risks such as gastrointestinal symptoms, pancreatitis, and thyroid cell neoplasia ...
Meshari A Turjoman, Amani Mahrous, Ahmed A Ozbuk, Raghad M Alhujaili, Hessan T Bagasi, Khulood A Alsiary   +5 more
doaj   +1 more source

Impact of GLP-1 Receptor Agonists on Perceived Eating Behaviors in Response to Stimuli

Diabetes, Metabolic Syndrome and Obesity
Carol Cheney,1 Krystal Hunter,1 Marlena Klein2 1Cooper Medical School of Rowan University, Camden, NJ, USA; 2Internal Medicine Department, Cooper University Hospital, Camden, NJ, USACorrespondence: Carol Cheney, Cooper Medical School of Rowan University,
Cheney C, Hunter K, Klein M
doaj  

GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity

The Journal of Clinical Investigation
Glucagon-like peptide-1 (GLP-1) was initially considered to be a hormone with a predominant role in regulating glucose metabolism by inducing insulin secretion, reducing glucagon secretion, and ameliorating insulin resistance, with the last effect being ...
Mark E. Cooper, Daniël H. van Raalte
doaj   +1 more source

Glucagon-Like Peptide-1 Receptor Agonist and Hyponatremia: A Potential Association. [PDF]

JACC Case Rep
Yeo YH, Dixon SR.
europepmc   +1 more source

Association between glucagon-like peptide-1 receptor agonist use and ischemic stroke severity. [PDF]

J Neurol Sci
Chen H, Lakhani DA, Yaddanapudi SS, Latifikhereshky S, Rai P, Kakadiya J, Malhotra A, Colasurdo M, Gandhi D.   +8 more
europepmc   +1 more source